Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

118.25USD
8:33pm IST
Change (% chg)

$-1.14 (-0.95%)
Prev Close
$119.39
Open
$118.82
Day's High
$119.23
Day's Low
$118.19
Volume
408,563
Avg. Vol
2,278,541
52-wk High
$126.07
52-wk Low
$91.78

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $326,636.31
Shares Outstanding(Mil.): 2,735.88
Dividend: 0.80
Yield (%): 2.68

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.24 37.70 37.57
EPS (TTM): 5.37 -- --
ROI: 13.31 14.41 13.91
ROE: 20.93 15.24 14.85

FDA approves J&J's autoimmune drug Stelara for Crohn's disease

Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease.

26 Sep 2016

FDA approves J&J's autoimmune drug Stelara for Crohn's disease

Sept 26 Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease.

26 Sep 2016

Abbott to sell its eye care business to J&J for about $4.33 billion

Abbott Laboratories said it would sell its eye care business to Johnson & Johnson for about $4.33 billion in cash to focus on cardiovascular devices and diagnostics business.

17 Sep 2016

UPDATE 3-Abbott to sell its eye care business to J&J for about $4.33 bln

Sept 16 Abbott Laboratories said it would sell its eye care business to Johnson & Johnson for about $4.33 billion in cash to focus on cardiovascular devices and diagnostics business.

17 Sep 2016

BRIEF-Abbott to sell Abbott Medical Optics to Johnson & Johnson for $4.325 bln

* Net impact of this transaction is not expected to impact Abbott's overall targeted ongoing earnings per share in 2017.

17 Sep 2016

BRIEF-Johnson & Johnson to buy Abbott Medical Optics for $4.325 bln

* Johnson & Johnson announces agreement to acquire Abbott Medical Optics

17 Sep 2016

Abbott in talks to sell its eye-surgery business to J&J - WSJ

Sept 16 Abbott Laboratories is in talks to sell its eye-surgery business to Johnson & Johnson, the Wall Street Journal reported, citing sources familiar with the matter.

16 Sep 2016

BRIEF-WellDoc announces agreement with LifeScan

* WellDoc announces agreement with LifeScan Inc, a Johnson & Johnson diabetes care company, to finalize commercial partnership to deliver combined, best-in-class digital therapeutic solution for patients with type 2 diabetes Source text for Eikon: Further company coverage:

13 Sep 2016

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video

23 Aug 2016

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.

23 Aug 2016

Earnings vs. Estimates